Beta Bionics priced an underwritten public offering of 7,652,175 common shares at USD 17.25 per share.
The company also sold pre-funded warrants for 1,043,484 shares at USD 17.2499, with a USD 0.0001 exercise price.
Gross proceeds are expected to be USD 150 million before fees, with closing targeted for Sept. 17, 2026.
Underwriters have a 30-day option to buy up to 1,304,348 additional shares at the offering price.
Net proceeds are earmarked for general corporate purposes, including Mint commercialization, manufacturing expansion, R&D, clinical development, and working capital.
BBNX•
